Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

• Main Authors: Christoph Lübbert (Author), Igor Dykukha (Author), Jann-Patrick Pelz (Author), Helen Yearley (Author), Wolfgang Junker (Author), Nina Gruber (Author), Sibyll Escher (Author), Katrin Biereth (Author), Sima Melnik (Author), Julia Puschmann (Author)
• Formato: Libro
• Publicado: BioExcel Publishing Ltd, 2023-06-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background: Nirmatrelvir/ritonavir is authorized for the treatment of COVID-19 but has several contraindications and potential drug-drug interactions (pDDIs) due to ritonavir-induced irreversible inhibition of cytochrome P450 3A4. We aimed to assess the prevalence of individuals with one or more ris...